We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
TWO lethal ‘legal highs’ should be controlled as class A substances, recommends the Advisory Council on the Misuse of Drugs (ACMD).
Health supplements boss who failed to rein in aggressive overseas call centre banned for nine years.
The design and content of the Patient Information Leaflets for methylphenidate products are being updated with the latest guidance on safe and effective use for patients and carers
The CMA has imposed over £100 million in fines after Advanz inflated the price of thyroid tablets, causing the NHS and patients to lose out.
A summary of letters and drug alerts recently sent to healthcare professionals.
The CMA investigated certain agreements relating to paroxetine under Chapter I and II of the CA98 and Article 101 of the TFEU.
Five projects will receive part of £5 million innovation fund to test new ways to reduce use of so-called recreational drugs.
First published during the 2022 to 2024 Sunak Conservative government
The new 'Shooting Up' report published today by PHE found patterns of injecting drug use are changing, but infection risk for all drug users remains high.
A change to the Misuse of Drugs Act 1971 to control 3 benzodiazepines (flualprazolam, flunitrazolam and norfludiazepam) under Class C.
The CMA has opened an investigation into suspected anti-competitive practices in the supply of drugs used to treat bipolar disorder.
Coalition government takes range of action to respond to challenges of new psychoactive substances.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
The government has issued serious shortage protocols (SSPs) to limit dispensing to 3 months’ supply for 3 HRT products to ensure continued access.
First published during the 2019 to 2022 Johnson Conservative government
Report finds prescription-only medicines are being used to supplement the use of other illicit drugs, including cocaine and heroin.
The CMA has completed its investigation into anti-competitive agreements in the pharmaceutical sector under Chapter I CA98 (case reference: 50511-2).
Decisions made by MHRA following investigations into complaints about advertising for licensed medicines.
Further information is available to support safer use
Experts have today called on the government to permanently ban two groups of “legal highs”.
Employment Tribunal decision.
Risk of early psychiatric side-effects is one of several important safety issues for healthcare professionals to discuss with patients and carers, who should seek urgent medical advice in the event of any worrying symptoms.
Public consultation published to prevent terrorists obtaining explosive precursors.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).